US 12215347
Chimeric antigen receptors with enhanced signaling and activities and uses thereof
granted A61KA61K2239/22A61K40/11
Quick answer
US patent 12215347 (Chimeric antigen receptors with enhanced signaling and activities and uses thereof) held by Allogene Therapeutics, Inc. expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Allogene Therapeutics, Inc.
- Grant date
- Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61K, A61K2239/22, A61K40/11, A61K40/31, A61K40/4202